133 related articles for article (PubMed ID: 15197355)
1. Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade.
Macpherson GR; Figg WD
Cancer Biol Ther; 2004 Jun; 3(6):503-4. PubMed ID: 15197355
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.
Welsh S; Williams R; Kirkpatrick L; Paine-Murrieta G; Powis G
Mol Cancer Ther; 2004 Mar; 3(3):233-44. PubMed ID: 15026543
[TBL] [Abstract][Full Text] [Related]
3. New drugs target hypoxia response in tumors.
Garber K
J Natl Cancer Inst; 2005 Aug; 97(15):1112-4. PubMed ID: 16077066
[No Abstract] [Full Text] [Related]
4. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice.
Jacoby JJ; Erez B; Korshunova MV; Williams RR; Furutani K; Takahashi O; Kirkpatrick L; Lippman SM; Powis G; O'Reilly MS; Herbst RS
J Thorac Oncol; 2010 Jul; 5(7):940-9. PubMed ID: 20512076
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer.
Kheshtchin N; Arab S; Ajami M; Mirzaei R; Ashourpour M; Mousavi N; Khosravianfar N; Jadidi-Niaragh F; Namdar A; Noorbakhsh F; Hadjati J
Cancer Immunol Immunother; 2016 Oct; 65(10):1159-67. PubMed ID: 27497816
[TBL] [Abstract][Full Text] [Related]
6. A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor.
Lee K; Kim HM
Arch Pharm Res; 2011 Oct; 34(10):1583-5. PubMed ID: 22076756
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha.
Koh MY; Spivak-Kroizman T; Venturini S; Welsh S; Williams RR; Kirkpatrick DL; Powis G
Mol Cancer Ther; 2008 Jan; 7(1):90-100. PubMed ID: 18202012
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia inducible factor 1 inhibitors for cancer therapy.
Qing L; Qing W
Minerva Chir; 2019 Oct; 74(5):442-444. PubMed ID: 31115241
[No Abstract] [Full Text] [Related]
9. Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010).
Ban HS; Uto Y; Nakamura H
Expert Opin Ther Pat; 2011 Feb; 21(2):131-46. PubMed ID: 21210751
[TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.
Jordan BF; Runquist M; Raghunand N; Baker A; Williams R; Kirkpatrick L; Powis G; Gillies RJ
Neoplasia; 2005 May; 7(5):475-85. PubMed ID: 15967100
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.
Otrock ZK; Hatoum HA; Awada AH; Ishak RS; Shamseddine AI
Crit Rev Oncol Hematol; 2009 May; 70(2):93-102. PubMed ID: 19186072
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia inducible factor as a cancer drug target.
Welsh SJ; Powis G
Curr Cancer Drug Targets; 2003 Dec; 3(6):391-405. PubMed ID: 14683498
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors.
Chau NM; Rogers P; Aherne W; Carroll V; Collins I; McDonald E; Workman P; Ashcroft M
Cancer Res; 2005 Jun; 65(11):4918-28. PubMed ID: 15930314
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia inducible factor-1: a novel target for cancer therapy.
Belozerov VE; Van Meir EG
Anticancer Drugs; 2005 Oct; 16(9):901-9. PubMed ID: 16162966
[TBL] [Abstract][Full Text] [Related]
15. Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo.
Jordan BF; Black K; Robey IF; Runquist M; Powis G; Gillies RJ
NMR Biomed; 2005 Nov; 18(7):430-9. PubMed ID: 16206237
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia inducible factor-1alpha as a cancer drug target.
Powis G; Kirkpatrick L
Mol Cancer Ther; 2004 May; 3(5):647-54. PubMed ID: 15141023
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibition of hypoxia inducible factor-1alpha: a viable therapeutic approach?
Tew KD
Mol Cancer Ther; 2004 Mar; 3(3):245-6. PubMed ID: 15026544
[No Abstract] [Full Text] [Related]
18. Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.
Lang M; Wang X; Wang H; Dong J; Lan C; Hao J; Huang C; Li X; Yu M; Yang Y; Yang S; Ren H
Cancer Lett; 2016 Aug; 378(2):87-96. PubMed ID: 27212442
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway.
Tan C; de Noronha RG; Roecker AJ; Pyrzynska B; Khwaja F; Zhang Z; Zhang H; Teng Q; Nicholson AC; Giannakakou P; Zhou W; Olson JJ; Pereira MM; Nicolaou KC; Van Meir EG
Cancer Res; 2005 Jan; 65(2):605-12. PubMed ID: 15695405
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factor-1 as a therapeutic target in cancer.
Tang CM; Yu J
J Gastroenterol Hepatol; 2013 Mar; 28(3):401-5. PubMed ID: 23173651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
